AXSM Axsome Therapeutics, Inc.

177.08USD-1.21%Mkt Cap: 9.28B $P/E: —

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio …

Key Statistics

Company
Market Cap9.28B USD
Enterprise Value9.29B USD
Revenue (TTM)776.57M USD
Gross Profit591.02M USD
Net Income (TTM)-183.17M USD
Revenue/Share15.25 USD
Last Price177.08 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.3K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)35.61
PEG—
EV/EBITDA-53.75
EV/Revenue11.97
P/S12.09
P/B112.52
EPS (TTM)-3.74
EPS (Forward)5.03
52W Range
115.3143% of range260.19
52W High260.19 USD
52W Low115.31 USD
Profitability
Gross Margin92.56%
Oper. Margin-23.42%
EBITDA Margin-22.27%
Profit Margin-28.69%
ROE-207.46%
ROA-26.55%
Growth
Revenue Growth45.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-93.41M USD
CapEx (TTM)480.00K USD
FCF Margin-0.59%
FCF Yield-0.05%
Net Debt-95.16M USD
Net Debt/EBITDA0.55
Balance Sheet
Debt/Equity2.47
Current Ratio1.43
Quick Ratio1.30
Book Value/Sh1.59 USD
Cash/Share6.11 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)284.63 USD
Upside (mean)+60.7%
Target Range246.00 USD – 380.00 USD
246.00+60.7% to mean380.00
# Analysts22
Ownership
Shares Out.52.38M
Float44.46M
Insiders15.08%
Institutions74.64%
Short Interest
Short Ratio5.5d
Short % Float9.29%
Short % Out.5.99%
Shares Short3.14M
Short (prev mo.)3.21M
Technical
SMA 50209.41 (-15.4%)
SMA 200199.79 (-11.4%)
Beta0.71
S&P 52W Chg14.58%
Avg Vol (30d)656.81K
Avg Vol (10d)794.11K
Technical Indicators
RSI (14)26.9
MACD-9.1494
MACD Signal-7.0231
MACD Hist.-2.1263
BB Upper224.88 USD
BB Middle199.49 USD
BB Lower174.10 USD
BB Width25.46%
ATR (14)7.475 USD
Vol Ratio (20d)1.21x